MXPA05012619A - Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca. - Google Patents

Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.

Info

Publication number
MXPA05012619A
MXPA05012619A MXPA05012619A MXPA05012619A MXPA05012619A MX PA05012619 A MXPA05012619 A MX PA05012619A MX PA05012619 A MXPA05012619 A MX PA05012619A MX PA05012619 A MXPA05012619 A MX PA05012619A MX PA05012619 A MXPA05012619 A MX PA05012619A
Authority
MX
Mexico
Prior art keywords
cardiac hypertrophy
pkd
inhibition
treatment
hdacs
Prior art date
Application number
MXPA05012619A
Other languages
English (en)
Spanish (es)
Inventor
Rick B Vega
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MXPA05012619A publication Critical patent/MXPA05012619A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
MXPA05012619A 2003-05-21 2004-05-19 Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca. MXPA05012619A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47229803P 2003-05-21 2003-05-21
PCT/US2004/015715 WO2004112763A2 (en) 2003-05-21 2004-05-19 Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure

Publications (1)

Publication Number Publication Date
MXPA05012619A true MXPA05012619A (es) 2006-02-08

Family

ID=33539040

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012619A MXPA05012619A (es) 2003-05-21 2004-05-19 Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.

Country Status (9)

Country Link
US (1) US20050112128A1 (enExample)
EP (1) EP1631268A2 (enExample)
JP (1) JP2007505158A (enExample)
CN (1) CN1812776A (enExample)
AU (1) AU2004249114A1 (enExample)
BR (1) BRPI0410787A (enExample)
CA (1) CA2526423A1 (enExample)
MX (1) MXPA05012619A (enExample)
WO (1) WO2004112763A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
WO2005018673A1 (en) * 2003-08-21 2005-03-03 Osaka University Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby
US20090111868A1 (en) * 2004-12-02 2009-04-30 Marx Steven O Use Of Rottlerin And Its Derivatives As Activators Of BK Channel For Therapy Of Hypertension And Related Disorders
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1760092A1 (en) * 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System for screening cells for high expression of a protein of interest
WO2007084857A2 (en) * 2006-01-13 2007-07-26 President And Fellows Of Harvard College Methods and compositions for treating cell proliferative disorders
EP2004234A2 (en) * 2006-04-06 2008-12-24 Novartis AG Combination of organic compounds
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
WO2009062118A2 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
GB0810051D0 (en) * 2008-06-02 2008-07-09 Oxford Biodynamics Ltd Method of diagnosis
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
WO2013074587A1 (en) * 2011-11-16 2013-05-23 Duke University Bishophonate compositions and methods for treating and/or reducing cardiac dysfunction
US9132174B2 (en) * 2013-03-15 2015-09-15 Anchored Rsk3 Inhibitors, Llc Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
CN104558110B (zh) * 2013-10-21 2018-06-08 中国科学院大连化学物理研究所 具有ace抑制活性的多肽及其在降血压药物中的应用
CN104558114B (zh) * 2013-10-21 2018-06-08 中国科学院大连化学物理研究所 花粉中具有ace抑制活性的多肽及其应用
WO2015082716A1 (en) * 2013-12-06 2015-06-11 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
US9730916B2 (en) * 2014-02-27 2017-08-15 Chang Gung Memorial Hospital, Keelung Nutritional composition and method for improving heart failure
GB2527364A (en) * 2014-06-20 2015-12-23 Imp Innovations Ltd Treatment
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
EA035465B1 (ru) * 2015-06-09 2020-06-22 Байер Фарма Акциенгезельшафт 7-замещенные 1-арил-нафтиридин-3-амиды карбоновой кислоты в качестве положительных аллостерических модуляторов мускаринового рецептора m2, способ их получения, их применение для лечения и/или профилактики заболеваний и лекарственное средство, содержащее эти соединения
US10907153B2 (en) 2017-07-06 2021-02-02 Michael S. KAPILOFF Treatment of heart disease by inhibtion of the action of muscle A-kinase anchoring protein (mAKAP)
CN107811997A (zh) * 2017-11-10 2018-03-20 大连医科大学附属第医院 蛋白酶体抑制剂白藜芦醇在预防和治疗心血管疾病中的应用
CN108379585B (zh) * 2018-04-16 2020-10-16 复旦大学附属中山医院 Hdac4抑制剂在制备治疗心力衰竭的药物中的应用
US20210206805A1 (en) 2018-05-23 2021-07-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cardiac-specific targeting-peptide (ctp), compositions, and uses thereof
WO2020058072A1 (en) * 2018-09-18 2020-03-26 Société des Produits Nestlé S.A. Src inhibitor compounds for skeletal muscle modulation, methods and uses thereof
CN109321602B (zh) * 2018-10-16 2021-11-30 汉恒生物科技（上海）有限公司 Pkd2重组过表达载体及其构建方法和用途
SG11202112499VA (en) 2019-05-15 2021-12-30 Univ Miami Treatment of heart disease by disruption of the anchoring of pp2a
CN112451529A (zh) * 2020-12-18 2021-03-09 忻佑康医药科技(南京)有限公司 Kb-NB 142-70的药物新用途
WO2022235771A1 (en) * 2021-05-04 2022-11-10 Enalare Therapeutics Inc. Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof
CN116942822A (zh) * 2023-06-12 2023-10-27 深圳大学 Hdac2在治疗室性心律失常中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) * 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4415723A (en) * 1982-03-19 1983-11-15 General Electric Company Randomly branched aromatic polycarbonate from triphenol
US6080784A (en) * 1986-06-11 2000-06-27 Procyon Pharmaceuticals, Inc. Protein kinase C modulators N
US6043270A (en) * 1986-06-11 2000-03-28 Procyon Pharmaceuticals, Inc. Protein kinase C modulators V
US5955501A (en) * 1986-06-11 1999-09-21 Procyon Pharmaceuticals, Inc. Protein kinase C modulators O
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
FR2685346B1 (fr) * 1991-12-18 1994-02-11 Cis Bio International Procede de preparation d'arn double-brin, et ses applications.
TW215434B (enExample) * 1992-03-07 1993-11-01 Hoechst Ag
US5889136A (en) * 1995-06-09 1999-03-30 The Regents Of The University Of Colorado Orthoester protecting groups in RNA synthesis
WO1997015575A1 (en) * 1995-10-27 1997-05-01 Procyon Pharmaceuticals, Inc. Protein kinase c modulators. y.
US6228843B1 (en) * 1999-04-23 2001-05-08 University Technology Corporation Method of using PKC inhibiting compounds to treat vascular disease
US6372468B1 (en) * 2000-09-14 2002-04-16 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
US20030134774A1 (en) * 2001-06-15 2003-07-17 Steinberg Susan F. Methods for inhibiting cardiac disorders
US6706686B2 (en) * 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
AU2003222513A1 (en) * 2002-03-08 2003-09-22 Protemix Corporation Limited Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
US20030229030A1 (en) * 2002-06-11 2003-12-11 Theoharides Theoharis C. Method of treating interleukin-6-mediated inflammatory diseases
EP1546369A4 (en) * 2002-08-12 2007-01-17 Univ Michigan DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD
AU2003214725A1 (en) * 2002-08-20 2004-03-11 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure

Also Published As

Publication number Publication date
WO2004112763A3 (en) 2005-09-09
JP2007505158A (ja) 2007-03-08
EP1631268A2 (en) 2006-03-08
WO2004112763A2 (en) 2004-12-29
BRPI0410787A (pt) 2006-06-20
CN1812776A (zh) 2006-08-02
US20050112128A1 (en) 2005-05-26
AU2004249114A1 (en) 2004-12-29
CA2526423A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
CO2024014194A2 (es) Compuestos de modulación de kras g12d
WO2004112763A3 (en) Inhibition of protein kinase c-mu (pkd) as a treatment for cardiac hypertrophy and heart failure
CO2020014217A2 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CR20120356A (es) Nuevos compuestos heterocíclicos activos como inhibidores de beta-lactamasas
CU23550B7 (es) Derivados de pirrolo-pirazol sustituidos como inhibidores de quinasa
CR8487A (es) Derivados de indazole como inhibidores de una hormona sensitiva a la lipasa
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
MX2023005628A (es) Metodos para aumentar y/o estabilizar la funcion cardiaca en pacientes con enfermedad de fabry.
EP2178869A4 (en) INDOL COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
SV2004001599A (es) Derivados de indol o de bencimidazol para modula ikb quinasa
UA89220C2 (ru) Способ лечения вич/спида путем приема без пищи или в условиях голодания твердого фармацевтического дозированного состава ингибитора вич-протеазы
ECSP056020A (es) Inhibidores del factor inhibidor de la migración de los macrofagos y metodos para su identificacion
GT200600028A (es) Compuestos y composiciones como inhibidores de proteina kinasa
CR20110131A (es) Derivados de prostaglandinas
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
DK1556371T3 (da) Benzimidazol-derivater og deres anvendelse som prodrugs for protonpumpe-inhibitorer
CL2022002148A1 (es) Inhibidores heterocíclicos de pad4
MX2023003199A (es) Vacuna contra la enfermedad por coronavirus de 2019 (covid-19) basada en el virus de la parainfluenza 5 (piv5).
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
AR103648A1 (es) Terapia de combinación contra el cáncer
CU20250021A7 (es) Compuesto inhibidor de la pde4b,útil para el tratamiento de enfermedades mediadas por pde4b
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).

Legal Events

Date Code Title Description
FA Abandonment or withdrawal